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Abstract
Background: Studies have come to conflicting conclusions about whether adiponectin (APN) expression is
associated with cancer prognosis. To help resolve this question, we meta-analyzed the available evidence.
Methods: PubMed, EMBASE, the Cochrane Library, the Chinese Biological Medical Database and the Chinese
National Knowledge Infrastructure Database were systematically searched to identify all eligible studies examining
APN expression and prognosis for patients with any type of cancer. Pooled hazard ratios (HRs) and corresponding
95 % confidence intervals (CIs) related to overall survival (OS) or disease-free survival (DFS) were calculated.
Results: Ten studies involving 999 patients were meta-analyzed. Analysis across all patients revealed no significant
association between high/positive APN expression and DFS, but they did show a significant association between
high/positive APN expression and OS (HR 1.51, 95 %CI 1.21 to 1.89). Subgroup analysis showed that high/positive
APN expression in non-Asians was significantly associated with both DFS (HR 1.36, 95 % CI 1.03 to 1.80) and OS
(HR 1.53, 95 %CI 1.20 to 1.96), but no such associations were observed in Asians. In addition, high/positive APN
expression was significantly associated with OS across all patients with hepatocellular carcinoma (HR 1.89, 95 %CI
1.20 to 2.98).
Conclusions: The available evidence suggests that high/positive APN expression is associated with poor
prognosis for patients with various carcinomas, especially for non-Asian cancer patients and for all patients with
hepatocellular carcinoma. These findings should be confirmed and extended in large, well-designed studies.
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Background
Cancer remains a frequent cause of death worldwide,
even though diagnostic and operative techniques have
improved dramatically. In 2008, approximately 12.7,000
000 people were diagnosed with cancer around the
world, and 7.6,000 000 people died from cancer-related
causes [1]. This highlights the continuing importance of
identifying prognostic factors that can better guide
survival prediction as well as treatment and management
strategies.
Large epidemiological studies have shown a significant
association of obesity with various carcinomas, including
breast, colorectal, renal, endometrial, pancreatic, esopha-
geal, and biliary [2–4]. This implies that the prevalence of
obesity, in part, which has been rising in parallel with liv-
ing standards in developed or developing countries, will
contribute to increasing incidence rates of many cancers.
One link between obesity and cancer may be adipo-
nectin (APN), also called gelatin-binding protein 28,
which is the most abundant of several adipokines se-
creted primarily by adipose tissue [5]. APN may play a
major role in cancer, and several studies suggest it may
also be a prognostic factor for cancer patients, but results
from prognostic studies have often been contradictory.
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For example, studies have shown that increased APN may
be associated with poor survival in patients with hepato-
cellular carcinoma (HCC) [6, 7], whereas a third study
found high APN expression to be associated with favor-
able prognosis in such patients [8]. One study reported
that elevated APN levels were associated with reduced
disease-free survival (DFS) of patients with breast cancer
[9], while another failed to find any significant association
between APN expression and prognosis of such patients
[10]. Other studies have similarly failed to find a signifi-
cant relationship between APN expression and survival in
patients with lung or gastric cancer [11, 12]. One study
reported an association between high APN levels and poor
survival in patients with childhood non-Hodgkin’s lymph-
oma [13].
To address more comprehensively the question of
whether APN expression is associated with cancer prog-
nosis, and to examine whether this association depends
on patient or cancer characteristics, we systematically
searched the research literature and meta-analyzed avail-
able evidence. As far as we know, this is the first re-
ported meta-analysis of the association between APN
expression and cancer prognosis.
Patients and methods
Literature searching
PubMed, EMBASE, the Cochrane Library, the Chinese
Biological Medical (CBM) database and the Chinese Na-
tional Knowledge Infrastructure (CNKI) database were
systematically searched to identify studies published
through February 30, 2015 that examined the association
between APN expression and cancer prognosis. Searches
were carried out without restrictions on publication lan-
guage using various combinations of customized terms
and the MeSH-indexed terms “adiponectin”, “prognosis”,
“outcome”, “survival”, and “cancer”. The following se-
quential search strategy was applied for each database:
(#1) ‘adiponectin’: ab, ti OR ‘APN’: ab, ti OR ‘adiponectin’/
exp; (#2) ‘survival’: ab, ti OR ‘prognosis’: ab, ti OR ‘prog-
nostic’: ab, ti OR ‘outcome’: ab, ti OR ‘prognosis’/exp OR
‘treatment outcome’/exp; (#3) ‘neoplasm’: ab, ti OR ‘can-
cer’: ab, ti OR ‘carcinoma’: ab, ti OR ‘tumor’: ab, ti OR
‘neoplasm’/exp OR ‘carcinoma’/exp; (#4) #1 AND #2 AND
#3, but search strings were adjusted accordingly for the
other databases. Reference lists in identified articles were
searched manually to identify additional studies.
Study inclusion and exclusion
Inclusion and exclusion criteria were established before
searching the literature. To be included in our meta-
analysis, studies had to (1) investigate the correlation be-
tween APN expression and prognosis of cancer patients,
and (2) provide sufficient information to obtain the
hazard ratio (HR) and 95 % confidence intervals (CIs)
related to overall survival (OS) or DFS.
Reviews, abstracts submitted to a conference, letters to
the editor, case reports and comments were excluded.
When studies reported on the same or overlapping pa-
tient populations, only the study with the most complete
data set and most rigorous methodology was used.
Data extraction
Two investigators (JXY, ZGL) independently extracted the
following data from included studies: first author’s name,
year of publication, country/region and ethnicity of study
population, type of cancer, number of patients, tumor
stage, follow-up period, method to detect APN expression,
cut-off value for APN positivity, and HRs with corre-
sponding 95%CIs. When HRs could not be directly ex-
tracted from original reports, they were extracted from
Kaplan-Meier curves as reported by Tierney et al. [14]. If
the original articles categorized APN expression levels into
tertiles, we extracted HRs and 95 %CIs relating the top
tertile to the bottom tertile, as described by Danesh et al.
[15], or we extracted HRs and 95 %CIs from Kaplan-
Meier curves. If a study reported HRs and 95 %CIs for
both univariate and multivariate analyses, only the results
of multivariate analysis were used.
Quality assessment
The quality of all eligible studies was evaluated using The
Quality In Prognosis Studies (QUIPS) tool [16, 17], which
bases its assessment on six study dimensions: study par-
ticipation, study attrition, prognostic factor measurement,
outcome measurement, confounder measurement and ap-
proaches for accounting and analyzing. For each dimen-
sion, an assessment of ‘Yes’ indicates a low risk of bias;
‘Partly’, moderate risk of bias; ‘No’, high risk of bias; and
‘Unsure’, unclear risk of bias. Each study was also assigned
an overall assessment of potential bias as low, moderate,
or high.
Statistical analysis
HRs with corresponding 95 %CIs were calculated
using RevMan 5.1.0 (The Cochrane Collaboration,
Oxford, UK) to assess the correlations between APN
expression and cancer prognosis, quantified in terms
of OS and DFS. Heterogeneity among studies was
assessed using the Q-test and I2 statistics. When
homogeneity was considered significant (Pheterogeneity ≥
0.1), a fixed-effect model was used; otherwise, a
random-effect model was used.
Subgroup analysis was also conducted according to pa-
tient ethnicity and cancer type. We planned to aggregate
together in a category of “other cancers” any studies that
were the only ones in the meta-analysis to cover a given
type of cancer.
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To assess publication bias, we performed Begg’s test [18]
and Egger’s test [19] using Stata 12.0 (Stata Corporation,
College Station, TX).
Results
Study selection and characteristics
The search strategy yielded 1066 records, from which
263 duplicate publications were eliminated and 789 were
excluded as irrelevant based on a review of titles and ab-
stracts. The remaining 14 studies were read in full to as-
sess eligibility. This led us to exclude three studies
because they failed to report sufficient information to es-
timate HRs and 95 %CIs [20–22], as well as one study
because it was a meta-analysis [23]. In the end, 10 stud-
ies were included in the meta-analysis [6–13, 24, 25]
(Fig. 1, Table 1).
Study quality
Quality assessment indicated that all 10 included studies
involved samples that were likely to represent the key
Fig. 1 Flow diagram of study selection for the meta-analysis
Table 1 Main characteristics of the studies included in the meta-analysis examining the relationship between adiponectin expression
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characteristics of the target population of cancer pa-
tients, reported data that adequately described the sam-
ple, assessed adequately the prognostic factor(s) of
interest in study participants and used statistical analysis
appropriate to the study design. However, three studies
[6, 11, 12] did not report the duration of follow-up, so
they received an assessment of “Partly” on the dimension
of outcome measurement. In five studies [7, 8, 10, 11, 25],
important potential confounders were not matched be-
tween cases and controls analyzed. Since three of these
studies [7, 8, 10] adequately measured potential confound-
ing variables using prespecified multivariate analysis, they
were assessed with “Yes” on the dimension of confounder
measurement and accounting; the remaining two studies
[11, 25] received an assessment of “No”.
Altogether, six of the 10 studies were judged to have
low overall risk of bias, two to have moderate overall
risk of bias, and two to have high risk of bias (Table 2).
APN expression and OS
Pooling data from eight studies [6–8, 10–13, 24] showed
that high/positive expression of APN was significantly
associated with OS in patients with various carcinomas
(HR 1.51, 95 %CI 1.21 to 1.89; Fig. 2).
Subgroup analysis by patient ethnicity and tumor
type (Figs. 2 and 3) showed a significant relationship
between high/positive APN expression and OS in
non-Asian patients (HR 1.53, 95 %CI 1.20 to 1.96),
but not in Asian patients (HR 1.41, 95 %CI 0.81 to
2.46). The association between high/positive APN
expression and OS was also observed among patients
with HCC (HR 1.89, 95 %CI 1.20 to 2.98) and “other
cancers”.
APN expression and DFS
Pooling data from six studies [8–10, 13, 24, 25]
showed no significant association between high/posi-
tive APN expression and DFS in patients with various
cancers (HR 1.15, 95 %CI 0.92 to 1.45; Fig. 4). Similar
negative results were obtained in subgroup analyses
(breast cancer: HR 1.22, 95 %CI 0.77 to 1.62; Figs. 4
and 5), with the exception of analysis by patient eth-
nicity: in non-Asian cancer patients, high/positive
APN expression was significantly associated with DFS
(HR 1.36, 95 %CI 1.03 to 1.80).
Publication bias
Egger’s and Begg’s tests to assess risk of publication bias
suggested no significant risk, with the respective tests
returning P values of 0.425 and 0.386.
Discussion
Despite numerous studies examining a possible link
between APN expression and cancer prognosis, the evi-
dence remains unclear. Combining the statistical power
of 10 studies involving 999 patients, the present meta-
analysis suggests that positive/high APN expression is
not significantly associated with DFS in various carcin-
omas but is significantly associated with OS (HR 1.51,
95 %CI 1.21 to 1.89). This suggests that positive/high
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APN expression may be a useful biomarker to predict
poor prognosis in patients with various carcinomas.
Subgroup analyses suggest that the relationship of
APN expression with DFS and OS may depend on pa-
tient ethnicity. While APN expression was not signifi-
cantly associated with either DFS or OS among Asian
patients with various cancers, it was associated with both
outcomes in non-Asian patients (DFS, HR 1.36, 95 %CI
1.03 to 1.80; OS, HR 1.53, 95 %CI 1.20 to 1.96). This dif-
ferential ethnic effect may reflect differences in genetic
background, lifestyle, dietary habits, and environmental
factors.
Subgroup analyses further suggest that the relationship
of APN expression with DFS and OS may depend on
tumor type. Thus, high/positive APN expression had no
association with DFS in patients with breast cancer, but
correlated with OS in patients with HCC (HR 1.89, 95
%CI 1.20 to 2.98). Unfortunately our meta-analysis was
unable to provide a clear answer about a possible associ-
ation between APN expression and prognosis for other
types of cancer because too few studies in our data set
of each tumor type. This highlights the need for large,
well-controlled studies of APN expression in other
cancers.
Fig. 3 Forest plot of the relationship between APN expression and OS across all patients with different cancers
Fig. 2 Forest plot of the relationship between APN expression and OS in Asians and non-Asians with a variety of cancers
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Our findings that elevated APN expression is associ-
ated with poor cancer prognosis are consistent with a
meta-analysis of 16 prospective studies involving 14,063
subjects, which showed that high APN level is associated
with increased risk of mortality in patients with cardio-
vascular disease [26]. Prospective analysis of 1000
community-dwelling adults 65 years and older suggested
that high APN concentration is significantly associated
with increased risk of all-cause and cardiovascular
mortality [27].
These findings seem paradoxical given that many stud-
ies in vitro and in vivo have shown APN to have signifi-
cant anti-diabetic, anti-atherosclerotic, anti-inflammatory,
anti-proliferative and anti-carcinogenic activity [28].
Several mechanisms have been proposed to explain this
so-called “adiponectin paradox”. One possibility is APN
resistance: even when APN is abundantly expressed, it
may fail to protect against poor prognosis because the
APN receptor is down-regulated or the APN signaling
pathway is dysfunctional. Indeed, many patients with
HCC have liver fibrosis or cirrhosis, both of which have
been associated with APN receptor down-regulation in
liver tissue and reduced clearance of APN, resulting in a
state of APN resistance [29–31]. Another possible mech-
anism of APN resistance is that APN expression initially
increases to compensate for disease progression, but the
higher levels of APN turn out to be ineffective because of
overall deterioration of the patient’s condition [26].
A second possible explanation of the adiponectin
paradox is that APN promotes AKT-mediated activa-
tion of cancer cells [5, 6, 32]; such activation is a sig-
nificant predictor of worse survival [33, 34]. A third
possible explanation is that APN promotes angiogenesis
in tumors [35–37].
The results of our meta-analysis are consistent with
those of an earlier meta-analysis [23] involving 705 HCC
Fig. 5 Forest plot of the relationship between APN expression and DFS across all patients with different cancers. a. Forest plot of breast cancer in
fixed-effect model; b. Forest plot of cancers other than breast cancer in random-effect model
Fig. 4 Forest plot of the relationship between APN expression and DFS in Asians and non-Asians with a variety of cancers
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patients and 1390 healthy controls, which found signifi-
cantly higher serum APN levels in HCC patients than in
healthy controls. Those authors concluded, paradoxic-
ally, that elevated serum APN levels may be associated
with slower progression of HCC patients, but they did
not support their claim with survival data. The present
meta-analysis, in contrast, is based on rigorous assess-
ment of OS and DFS in the literature.
Despite its strengths, our meta-analysis has several
limitations. First, the accuracy of the meta-analysis may
be affected by the variety of APN cut-off values used to
detect expression in the included studies. Second, we ex-
tracted several HRs from survival curves or HRs for top
and bottom tertiles in the original articles, which may
have introduced small errors. Third, though our analyses
suggested no significant risk of publication bias, the
meta-analysis included a small number of studies in glo-
bal or subgroup analyses, it might result in little bias of
finding. Fourth, the patient populations were heteroge-
neous because they had different types of cancer. More-
over, different detected specimens (tumor tissue or
serum) and detected methods might also increase the
risk of bias. Therefore, these findings should be used
with caution.
Conclusions
The available evidence suggests that high/positive APN
expression is associated with poor prognosis for patients
with various carcinomas, especially for non-Asian cancer
patients and for all patients with hepatocellular carcin-
oma. Future studies should confirm and extend our
findings. In particular, large, well-designed studies are
needed to examine the possible association of APN ex-
pression with prognosis in non-HCC cancers in Asians
and non-Asians.
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